Litcius/Paper detail

Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review

Suwen Hu, Songwei Jiang, Qi Xiang, Renren Bai, Xiang‐Yang Ye, Tian Xie

2021Drug Development Research84 citationsDOIOpen Access PDF

Abstract

The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.

Topics & Concepts

RepurposingCoronavirus disease 2019 (COVID-19)Clinical trialPandemicDrug repositioningSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusMedicineDrug developmentIntensive care medicineOutbreakDiseaseDrugPharmacologyInfectious disease (medical specialty)BiologyVirologyPathologyEcologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Immunology Research
Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review | Litcius